Academic Journal
Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset
| العنوان: | Efficacy of Isatuximab With Pomalidomide and Dexamethasone in Relapsed Myeloma: Results of a UK-Wide Real-World Dataset |
|---|---|
| المؤلفون: | Djebbari, F., Rampotas, A., Vallance, G., Panitsas, F., Basker, N., Sangha, G., Salhan, B., Karim, F., Al-Kaisi, F., Gudger, A., Ngu, L., Poynton, M., Lam, H. P. J., Morgan, L., Yang, L., Young, J., Walker, M., Tsagkaraki, I., Anderson, L., Chauhan, S. R., Maddams, R., Soutar, R., Triantafillou, M., Prideaux, S., Obeidalla, A., Bygrave, C., Basu, S., Ramasamy, K. |
| بيانات النشر: | Lippincott, Williams & Wilkins |
| سنة النشر: | 2022 |
| المجموعة: | RD&E Research Repository (Royal Devon and Exeter NHS Foundation Trust) |
| الوصف: | Real-world data on the efficacy and tolerability of isatuximab with pomalidomide and dexamethasone (IsaPomDex) in relapsed/refractory myeloma patients have not been reported. In this UK-wide retrospective study, IsaPomDex outcomes were evaluated across 24 routine care cancer centers. The primary endpoint was overall response rate (ORR). Secondary endpoints included progression-free survival (PFS), duration of response (DOR) for patients who achieved an objective response (≥partial response [PR]), and adverse events (AEs). In a total cohort 107 patients, median follow up (interquartile range [IQR]) was 12.1 months (10.1-18.6 mo), median age (IQR) was 69 years (61-77). Median (IQR) Charlson Comorbidity Index (CCI) score was 3 (2-4); 43% had eGFR <60 mL/min. Median (IQR) number of prior therapies was 3 (3-3). Median (IQR) number of IsaPomDex cycles administered was 7 (3-13). ORR was 66.4%, with responses categorized as ≥ very good partial response: 31.8%, PR: 34.6%, stable disease: 15.9%, progressive disease: 15%, and unknown 2.8%. Median PFS was 10.9 months. Median DOR was 10.3 months. There was no statistical difference in median PFS by age (<65: 10.2 versus 65-74 13.2 versus ≥75: 8.5 mo, log-rank P = 0.4157), by CCI score (<4: 10.2 mo versus ≥4: 13.2, log-rank P = 0.6531), but inferior PFS was observed with renal impairment (≥60: 13.2 versus <60: 7.9 mo, log-rank P = 0.0408). Median OS was 18.8 months. After a median of 4 cycles, any grade AEs were experienced by 87.9% of patients. The most common ≥G3 AEs were neutropenia (45.8%), infections (18.7%), and thrombocytopenia (14%). Our UK-wide IsaPomDex study demonstrated encouraging efficacy outcomes in the real world, comparable to ICARIA-MM trial. ; Published version, accepted version, submitted version ; The article is available via Open Access. Click on the 'Additional link' above to access the full-text. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/35651713/; Hemasphere. 2022 May 26;6(6):e738. doi:10.1097/HS9.0000000000000738. eCollection 2022 Jun.; HemaSphere; PMC9148694; https://hdl.handle.net/11287/622573 |
| DOI: | 10.1097/hs9.0000000000000738 |
| الاتاحة: | https://hdl.handle.net/11287/622573 https://doi.org/10.1097/hs9.0000000000000738 |
| Rights: | Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association. ; http://creativecommons.org/publicdomain/zero/1.0/ |
| رقم الانضمام: | edsbas.ABDB20FF |
| قاعدة البيانات: | BASE |
| DOI: | 10.1097/hs9.0000000000000738 |
|---|